| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | MEK1, MKK1, MAPKK1, PRKMK1 |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human MAP2K1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MAP2K1抗体的3篇参考文献示例(内容基于模拟生成，非真实文献)：
1. **文献名称**：*"Characterization of MAP2K1 mutations in melanoma using a phospho-specific antibody panel"*
**作者**：Davies, H. et al.
**摘要**：研究利用针对MAP2K1磷酸化位点的特异性抗体，通过Western blot和免疫组化分析黑色素瘤中MAP2K1突变体的激活状态，揭示了其与BRAF抑制剂耐药性的关联。
2. **文献名称**：*"Development and validation of a monoclonal antibody targeting the kinase domain of MAP2K1 for diagnostic applications"*
**作者**：Roberts, P.J. & Smith, C.R.
**摘要**：报道了一种高特异性MAP2K1单克隆抗体的开发，通过CRISPR敲除细胞系验证其特异性，并应用于结直肠癌组织芯片分析，显示MAP2K1过表达与预后不良相关。
3. **文献名称**：*"MAP2K1 signaling dynamics in ERK pathway activation revealed by antibody-based multiplex assays"*
**作者**：Roskoski, R. et al.
**摘要**：通过多抗体组合检测(包括MAP2K1抗体)研究ERK通路动态调控，发现MAP2K1的磷酸化水平在生长因子刺激后快速升高，并与下游ERK活性呈正相关。
4. **文献名称**：*"Therapeutic targeting of MAP2K1 in BRAF-mutant cancers: Antibody-based detection of isoform-specific expression"*
**作者**：Pratilas, C.A. et al.
**摘要**：利用MAP2K1亚型特异性抗体评估其在BRAF突变肿瘤中的表达模式，为MEK抑制剂的联合治疗策略提供分子标志物依据。
(注：以上文献为示例性内容，实际引用时请查询真实数据库如PubMed并核实原文信息。)
The MAP2K1 antibody is a crucial tool in studying the mitogen-activated protein kinase (MAPK) signaling pathway. MAP2K1. also known as MEK1. is a dual-specificity kinase that phosphorylates and activates downstream extracellular signal-regulated kinases (ERK1/2). This pathway regulates cellular processes like proliferation, differentiation, and apoptosis. Dysregulation of MAP2K1. often due to mutations (e.g., BRAF-driven activation), is implicated in cancers, autoimmune disorders, and developmental defects.
MAP2K1 antibodies are widely used in research to detect protein expression, localization, and activation status (via phospho-specific variants) in tissues or cell lines. They aid in elucidating pathway dynamics under physiological or pathological conditions, including drug resistance mechanisms in targeted cancer therapies. Commercial antibodies target specific epitopes, often distinguishing between MAP2K1 isoforms (e.g., MEK1 vs. MEK2) or phosphorylation states (e.g., p-Ser222). Validation methods include Western blot, immunohistochemistry (IHC), and immunofluorescence (IF).
These antibodies are vital for preclinical studies, especially in cancers with RAS/RAF mutations, enabling the assessment of therapeutic responses to MEK inhibitors. Researchers also use them to explore cross-talk with other pathways, offering insights into combination therapies. Proper antibody selection ensures specificity, minimizing cross-reactivity with homologous kinases, which is critical for accurate experimental outcomes.
×
